2型糖尿病合并超重或肥胖中老年人的骨折预测因素
该研究为Look AHEAD随机临床试验的二次分析,纳入4703例45-75岁2型糖尿病且BMI≥25 kg/m2的参与者,中位随访12.2年。噻唑烷二酮类(HR 1.22;95%CI 1.02-1.46)和胰岛素使用(HR 1.34;95%CI 1.08-1.66)是全因临床骨折的显著糖尿病相关预测因素;在亚队列(n=1285)中,全髋骨密度是全因临床骨折最强的可改变预测因素(每增加1 SD=0.1 g/cm2,HR 0.47;95%CI 0.39-0.58)。
要点
- 噻唑烷二酮类和胰岛素使用是2型糖尿病合并超重或肥胖者临床骨折的显著预测因素。
- 全髋骨密度每增加1 SD(0.1 g/cm2),全因临床骨折风险HR为0.47(95%CI 0.39-0.58)。
- 作者认为,若处方这些药物,评估骨密度是可取的;骨折风险预测工具可考虑纳入噻唑烷二酮类和胰岛素使用。
核心结论
- 噻唑烷二酮类和胰岛素使用预测2型糖尿病合并超重或肥胖中老年人的临床骨折。
- 作者认为,若处方这些药物,评估骨密度是可取的。
- 作者认为,骨折风险预测工具可考虑纳入噻唑烷二酮类和胰岛素使用,以细化该人群的预测。
研究设计与样本
- 该研究为美国多中心Look AHEAD:Action for Health in Diabetes随机临床试验的二次分析,随机化时间为2001年至2004年,骨折随访至2015年。
- 参与者为45至75岁、患有2型糖尿病且体重指数≥25 kg/m2的男性和女性。
- 在随机化时评估的潜在骨折预测因素包括传统和糖尿病相关危险因素(糖尿病病程、糖尿病神经病变、抗糖尿病药物使用、糖化血红蛋白和肾功能);在亚队列中测量全髋骨密度。
- 主要结局为所有 incident 临床骨折,通过自我报告确定并经医疗记录审查集中裁定。
主要发现
- 在中位12.2年随访期间,4703名参与者中有649人经历了至少一次临床骨折。
- 噻唑烷二酮类使用(HR 1.22;95%CI 1.02-1.46)和胰岛素使用(HR 1.34;95%CI 1.08-1.66)是所有临床骨折的显著糖尿病相关预测因素。
- 在亚队列(n=1285)中测量时,全髋骨密度是所有临床骨折最强的可改变预测因素(每增加1 SD=0.1 g/cm2,HR 0.47;95%CI 0.39-0.58)。
临床怎么用
- 作者认为,若处方噻唑烷二酮类或胰岛素,评估骨密度是可取的。
- 作者认为,骨折风险预测工具可考虑纳入噻唑烷二酮类和胰岛素使用,以细化该人群的预测。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Persons with type 2 diabetes have increased fracture risk that existing fracture risk assessment tools underestimate. OBJECTIVE: Identify fracture predictors in persons with type 2 diabetes and overweight or obesity, considering traditional and diabetes-related risk factors. METHODS: This is a secondary analysis of a multicenter US study, the Look AHEAD: Action for Health in Diabetes randomized clinical trial, with randomization from 2001 to 2004 and fracture follow-up until 2015. Participants were men and women 45 to 75 years old with type 2 diabetes and body mass index ≥ 25 kg/m2. Potential fracture predictors ascertained at randomization included traditional and diabetes-related risk factors (diabetes duration, diabetic neuropathy, antidiabetic medication use, hemoglobin A1c, and renal function). Total hip bone mineral density (BMD) was measured in a subcohort. Primary outcome was all incident clinical fractures, ascertained by self-report and centrally adjudicated with medical records review. RESULTS: Over a median 12.2-year follow-up, 649 of the 4703 participants experienced at least one clinical fracture. Thiazolidinedione use (hazard ratio [HR] 1.22; 95% CI, 1.02-1.46) and insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures. When measured in a subcohort (n = 1285), total hip BMD was the strongest modifiable predictor of all clinical fractures (per 1 SD = 0.1 g/cm2 increase, HR 0.47; 95% CI, 0.39-0.58). CONCLUSION: Thiazolidinedione and insulin use predict clinical fracture in middle-aged and older persons with type 2 diabetes and overweight or obesity. Evaluating BMD is advisable if these medications are prescribed. Fracture risk prediction tools may consider including thiazolidinedione and insulin use to refine prediction in this population.
引用
- Elam RE, Johnson KC, Xu H, et al. Predictors of Fracture in Middle-Aged and Older Adults With Type 2 Diabetes and Overweight or Obesity. J Clin Endocrinol Metab. 2025. PMID: 39259653. doi:10.1210/clinem/dgae623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。